FY2027 Earnings Estimate for ELVN Issued By HC Wainwright

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Analysts at HC Wainwright issued their FY2027 earnings estimates for Enliven Therapeutics in a research note issued to investors on Monday, October 19th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($2.06) per share for the year. HC Wainwright currently has a “Buy” rating and a $73.00 target price on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.81) per share.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10).

ELVN has been the subject of a number of other reports. The Goldman Sachs Group lifted their target price on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Barclays began coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price target on the stock. JonesTrading raised their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Guggenheim restated a “buy” rating on shares of Enliven Therapeutics in a report on Thursday, October 8th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $75.44.

Enliven Therapeutics Stock Up 3.7%

ELVN opened at $38.70 on Tuesday. The stock’s fifty day moving average is $51.60 and its two-hundred day moving average is $47.95. The company has a market capitalization of $2.84 billion, a P/E ratio of -23.17 and a beta of 0.24. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $62.32.

Insider Activity

In related news, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director directly owned 13,000 shares of the company’s stock, valued at $606,710. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $50.35, for a total transaction of $303,006.30. Following the transaction, the chief financial officer directly owned 38,000 shares in the company, valued at approximately $1,913,300. The trade was a 13.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 183,831 shares of company stock worth $10,823,298. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently bought and sold shares of the stock. KBC Group NV acquired a new position in Enliven Therapeutics during the 1st quarter valued at approximately $38,000. State of Wyoming purchased a new position in shares of Enliven Therapeutics in the second quarter worth $96,000. FNY Investment Advisers LLC acquired a new stake in shares of Enliven Therapeutics during the second quarter worth $126,000. Arizona State Retirement System lifted its stake in shares of Enliven Therapeutics by 45.1% during the second quarter. Arizona State Retirement System now owns 13,007 shares of the company’s stock worth $660,000 after buying an additional 4,042 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Enliven Therapeutics by 21.2% during the first quarter. The Manufacturers Life Insurance Company now owns 23,441 shares of the company’s stock worth $919,000 after buying an additional 4,105 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.